Stimulator of interferon genes (STING) is a promising target for cancer immunotherapy as its activation can overcome the suppressive tumour immune microenvironment. Although several STING agonists ...

GSK revealed the STING agonist cull in its third-quarter earnings (PDF) presentation, where the company also disclosed that two other candidates have been removed from its phase 1 pipeline.

Researchers have demonstrated a promising new approach to delivering immunotherapy agents to fight cancer. The approach involves tethering an immunotherapy agent called a STING agonist to an acid ...

Stimulator of interferon genes, or STING, agonists have enjoyed a bit of buzz over the past 10 years. | STING agonists have shown promise in preclinical research as mono- and adjunctive therapies ...

“Our STING agonist program builds upon the deep expertise we have developed in innate immunity through our work on CD47 and broadens our immuno-oncology pipeline,” said Dr. Niclas Stiernholm ...

Traditionally, therapies combining DNA-damaging agents and STING agonists have shown potential in treating cancer by enhancing immune response and reshaping the tumor microenvironment. However ...

The team suggested that STING agonists targeted specifically to tumor cells—not just cancer cells but also dormant immune cells within a tumor—may have significantly increased effectiveness.

In a pair of studies, researchers report the discovery and molecular pharmacology of stable, synthetic STING (stimulator of interferon genes) agonists that induce anticancer immune responses in mice.

In tumor-bearing mice, STING agonist administration significantly delayed tumor growth and increased radiotracer uptake in secondary lymphoid glands.

SB 11285 in Combination with Radiation is More Effective than Either as Monotherapy in a Murine Tumor Model SB 11285 is a Second Generation STING Agonist Delivered Intravenously CAMBRIDGE, United ...

Activating STING-mediated innate immunity requires second messenger molecules to bind onto the protein. In this next part of our series, we will delve deeper into the discovery that uncovered a ...